Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
Type:
Grant
Filed:
July 26, 2023
Date of Patent:
April 29, 2025
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Andrew B. Benowitz, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril, Megan Ketchum, Todd Koretke, Elizabeth Ann Moroz, Grace Price
Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
Type:
Application
Filed:
December 18, 2024
Publication date:
April 17, 2025
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Sanjay KHANDEKAR, Patrick MAYES, Joanna OPALINSKA
Abstract: Disclosed herein are novel processes for the production of oligonucleotides that are suitable for use in the production of chemically modified oligonucleotides, such as those for use in therapy.
Type:
Grant
Filed:
March 30, 2020
Date of Patent:
April 15, 2025
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Andreas Crameri, Malcolm Leithhead Hill, David Graham Tew
Abstract: The present invention relates to compounds of Formula (I), compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.
Type:
Application
Filed:
December 3, 2024
Publication date:
March 20, 2025
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Adam K. CHARNLEY, Janos Botyanszki, Xiaoyang Dong, Philip Gareth Humphreys, Bryan Wayne King, Kimberly Katherine Marcus, Joseph Pero, Alexander Joseph Reif, Daohua Zhang, Attiq Rahman, Kenneth Allen Newlander, Kenneth Wiggall, Joshi Ramanjulu
Abstract: Compounds of formula (1) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (1), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions.
Type:
Application
Filed:
December 16, 2021
Publication date:
March 13, 2025
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Abstract: The present invention relates to compounds of Formula (I), compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.
Type:
Grant
Filed:
February 26, 2024
Date of Patent:
March 11, 2025
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Adam K. Charnley, Janos Botyanszki, Xiaoyang Dong, Philip Gareth Humphreys, Bryan Wayne King, Kimberly Katherine Marcus, Joseph Pero, Alexander Joseph Reif, Daohua Zhang, Attiq Rahman, Kenneth Allen Newlander, Kenneth Wiggall, Joshi Ramanjulu
Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
Type:
Grant
Filed:
June 22, 2022
Date of Patent:
February 25, 2025
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Sanjay Khandekar, Patrick Mayes, Joanna Opalinska
Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
Type:
Grant
Filed:
August 22, 2023
Date of Patent:
February 18, 2025
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Sanjay Khandekar, Patrick Mayes, Joanna Opalinska
Abstract: Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.
Type:
Grant
Filed:
October 25, 2021
Date of Patent:
February 11, 2025
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
John G. Catalano, Pek Yoke Chong, Hamilton D. Dickson, Martin R. Leivers, Jason Gordon Weatherhead
Abstract: The present disclosure relates to pharmaceutical compositions comprising from about 100 mg to about 300 mg of an antigen binding protein which binds to IL-5. Compositions and antigen binding proteins of the disclosure are useful in the treatment of IL-5 mediated diseases, such as EGPA, HES, CRSsNP and CRSwNP, and can be administered about once every 6 months.
Type:
Application
Filed:
December 1, 2022
Publication date:
February 6, 2025
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Daren J. AUSTIN, Alienor C. BERGES, Nicholas P. BIRD, Myrna A. MONCK, Isabelle J. POULIQUEN, Melissa A. SHUMAN, Chiara ZECCHIN
Abstract: The present invention relates to methods of treating disease states, including cancer, in a human comprising systemically administering a STING agonist, or a pharmaceutically acceptable salt thereof, to said human.
Type:
Grant
Filed:
October 4, 2018
Date of Patent:
December 31, 2024
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
George Scott Pesiridis, Jean-Luc Tran, Jingsong Yang, Joshi M Ramanjulu
Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
Type:
Application
Filed:
September 3, 2024
Publication date:
December 26, 2024
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Gerben BOUMA, Edward Thomas COULSTOCK, David DIXON, Stephanie HOPLEY, Alan Peter LEWIS, Jessica Lynn NEISEN
Abstract: Disclosed herein are stable isotope labeling (SIL) peptide mapping methods for accurate and sensitive conjugation site quantitation. Also disclosed herein are compositions comprising antibody drug conjugates (ADCs) that target BCMA.
Type:
Application
Filed:
August 2, 2022
Publication date:
November 7, 2024
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Tyler Keith DAVIS, Hillary Amber SCHUESSLER
Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
Type:
Grant
Filed:
September 5, 2023
Date of Patent:
October 22, 2024
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Gerben Bouma, Edward Thomas Coulstock, David Dixon, Stephanie Hopley, Alan Peter Lewis, Jessica Lynn Neisen
Abstract: A modular production system including a plurality of production modules connected in a linear series to form a production tunnel, and collectively defining a production channel, and wherein at least one fluid inlet port defined along the production tunnel, said inlet port is in fluid communication with a pressurized fluid source, whereby influx of fluid from said fluid source through said fluid inlet port acts to maintain the fluid pressure within the production channel at a higher pressure than the atmospheric pressure outside of the production tunnel; and wherein one of said production modules positioned between said proximal-most and distal-most production modules comprises a depyrogenator and/or sterilization module, comprising a transparent tubular body, and an irradiation source positioned external to said transparent tubular body, said irradiation source capable of heating the internal environment of the depyrogenation and/or sterilization module to a temperature sufficient to depyrogenate or sterilize
Type:
Grant
Filed:
August 26, 2022
Date of Patent:
July 23, 2024
Assignee:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Abstract: The invention relates to compounds of Formula (I), (Ia), (II) or (IIa), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
Type:
Application
Filed:
November 14, 2023
Publication date:
June 6, 2024
Applicants:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, VIIV HEALTHCARE COMPANY
Inventors:
Martha Alicia DE LA ROSA, John F. MILLER, B. Narasimhulu NAIDU, Vicente SAMANO, David TEMELKOFF, Emile Johann VELTHUISEN
Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
Type:
Grant
Filed:
July 29, 2019
Date of Patent:
June 4, 2024
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.
Type:
Grant
Filed:
October 4, 2021
Date of Patent:
May 7, 2024
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Edward Brnardic, Michael Bury, Rodolfo Cadilla, Jon Collins, Yu Guo, Anthony Handlon, Huijie Li, Yue Li, Daniel Paone, Christie Schulte, Barry Shearer, Maben Ying, Guosen Ye, Huichang Zhang, Millard Hurst Lambert, III